Calidi Biotherapeutics Inc Stock Price, News & Analysis

Calidi Biotherapeutics (NYSE AMERICAN: CLDI), a clinical-stage biotechnology company focused on targeted immunotherapies, has announced plans for a public offering of common stock and pre-funded warrants. The offering will be conducted through Ladenburg Thalmann & Co. Inc. as the exclusive placement agent.

The company intends to use the proceeds for working capital and general corporate purposes. The securities will be offered through a shelf registration statement on Form S-3 that was declared effective by the SEC on October 10, 2024. The final size, terms, and completion of the offering are subject to market conditions.

A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC, providing detailed information about the offering terms.

Calidi Biotherapeutics presented data at IOVC and SITC conferences showcasing their RTNova™ systemic enveloped virotherapy technology for targeting metastatic lung cancer. The technology utilizes a tumor-selective vaccinia virus engineered to produce extracellular enveloped viruses (EEVs), designed to target multiple metastatic tumor sites while avoiding immune system clearance.

The data demonstrated RTNova's therapeutic potential in an advanced lung metastasis model, both as a monotherapy and as a viral vector for delivering therapeutic payloads. The technology shows promise in killing and transforming tumor microenvironments across multiple sites, potentially offering new treatment options for previously untreatable metastatic diseases.

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company focused on targeted antitumor virotherapies, has completed its previously announced public offering of 4,437,869 shares of common stock. The shares were priced at $1.69 per share, generating gross proceeds of approximately $7.5 million. Ladenburg Thalmann & Co. Inc. served as the exclusive placement agent for the offering, which was conducted under an effective Form S-3 registration statement.

Calidi Biotherapeutics (NYSE AMERICAN: CLDI) has announced the pricing of its public offering of 4,437,869 shares of common stock at $1.69 per share, expecting to raise approximately $7.5 million in gross proceeds. The offering is expected to close around November 15, 2024. Ladenburg Thalmann & Co. Inc. is serving as the exclusive placement agent. The company plans to use the net proceeds for working capital, general corporate purposes, and pre-clinical and clinical trials. The offering is being made through a shelf registration statement that was declared effective on October 10, 2024.

Calidi Biotherapeutics (NYSE AMERICAN: CLDI), a clinical-stage biotechnology company, has announced its intention to conduct a public offering of common stock and pre-funded warrants. The offering will be managed by Ladenburg Thalmann & Co. Inc. as the exclusive placement agent. The company plans to use the net proceeds for working capital and general corporate purposes. The securities are being offered through a shelf registration statement that was declared effective on October 10, 2024. The final size, terms, and completion of the offering are subject to market conditions.

Calidi Biotherapeutics (NYSE: CLDI) reported Q3 2024 financial results and key developments. The FDA cleared Northwestern University's IND application for NeuroNova (CLD-101), with Phase 1b/2 clinical trials in high-grade glioma expected to begin in early 2025. The company presented data on RTNova (CLD-400), their systemic antitumor virotherapy platform, at multiple conferences. Financially, Calidi reported a net loss of $5.1 million ($0.65 per share) compared to $2.0 million ($1.41 per share) in Q3 2023. The company raised $2 million through a registered direct offering and had $1.9 million in cash as of September 30, 2024.

Nexalin Technology (Nasdaq:NXL) and Calidi Biotherapeutics will be featured on Bloomberg TV's RedChip Small Stocks, Big Money show on October 26, 2024, at 7 p.m. ET. Nexalin's CEO Mark White will discuss their non-invasive neurostimulation technology for mental health treatment, including the Gen-3 HALO Clarity device, targeting a market projected to reach $537 billion by 2030. The technology addresses conditions like insomnia, PTSD, and traumatic brain injuries. Calidi's Chief Business Officer Stephen Thesing will present their oncolytic virotherapy developments for cancer treatment, featuring both systemic and localized approaches with engineered viruses protected by cell-based technologies.

Calidi Biotherapeutics (NYSE: CLDI) announces upcoming presentations of data supporting RTNova, their systemic antitumor virotherapy platform, at three major scientific conferences. The presentations will take place at the International Oncolytic Virotherapy Conference in Rotterdam (Oct 27-30), Immuno US 2024 in San Diego (Oct 28-30), and the Society for Immunotherapy of Cancer Annual Meeting in Houston (Nov 6-10).

RTNova is designed to target multiple tumor sites while evading the humoral immune system, offering potential treatment for previously untreatable metastatic diseases. The platform works by killing tumor cells and modifying the tumor immune microenvironment. Dr. Antonio Santidrian and Dr. Duong Nguyen will lead the presentations, sharing insights on this innovative therapeutic approach.

Calidi Biotherapeutics (NYSE AMERICAN: CLDI) has announced a $2 million registered direct offering and concurrent private placement. The company will sell 2,050,000 common stock shares at $1.00 per share, along with series E and F warrants to purchase up to 2,050,000 shares each at $1.13 per share. Series E warrants have a one-year term while Series F warrants extend to five years, both exercisable after six months. Ladenburg Thalmann & Co. Inc. is serving as exclusive placement agent. The proceeds will support working capital, general corporate purposes, and pre-clinical and clinical trials. The closing is expected around October 24, 2024.